Du Docteur Ruer S.E.L.A.R.L.

Running trials

• Recruiting

  A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis

  2024-519795-11-00· Phase 2· Source

• Recruiting

  Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation? Prospective multicenter interventional study

  2024-514647-29-01· Phase 2· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Source

• Active, not recruiting

  Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-508235-31-00· Phase 3· Source

• Active, not recruiting

  A Study Evaluating APG777 in Atopic Dermatitis

  NCT06395948· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT03568318· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Psoriasis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Source

• Completed

  A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

  NCT05923099· Phase 2· Source

• Completed

  Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  NCT03989206· Phase 3· Source

• Completed

  Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

  NCT03569293· Phase 3· Source